USFDA issues warning letter to Cipla for Goa manufacturing facility

Drug firm Cipla Ltd said that the US health regulator has issued a
warning letter to the company for its manufacturing facility in Goa.
The company further said that it remains committed to maintain highest
standards of compliance and will work closely with the agency to
comprehensively address all the observations.

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/usfda-issues-warning-letter-to-cipla-for-goa-manufacturing-facility/articleshow/74312928.cms

Comments

Popular posts from this blog

Clinical Database Management Professional Vacancy @ Teva

Pharma Production Executive Post Vacancy @ Intas

Biotecnika Times – Newsletter 28.02.2020 – DST Women Scientist WOS B, DBT-IOC Recruitment